MDS
MDS
Advertisement
Andrew MorenoASH 2024 | December 11, 2024
Daily oral administration of the agent brought favorable transfusion independence performance and overall safety.
Read More
Nichole TuckerASH 2024 | December 8, 2024
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Patrick DalyASH 2024 | December 7, 2024
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Nichole TuckerASH 2024 | December 7, 2024
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
Andrew MorenoASH 2024 | December 7, 2024
A transcriptomic analysis saw CDK8 repression increase expression of myeloid differentiation and oncogenesis genes in HSPCs.
Andrew MorenoASH 2024 | December 7, 2024
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
Andrew MorenoMDS | December 6, 2024
The investigators compiled patients' quality of life, social function, and physical scores, and assessed overall survival.
Andrew MorenoMDS | December 6, 2024
The US FDA conferred with experts on ways to improve CMML clinical trials and accelerate treatment advances in this disease.
Andrew MorenoMDS | December 5, 2024
Phase II trial results suggest limits to the IL-1β inhibitor's efficacy by patient genetic complexity and SF3B1 mutation.
Andrew MorenoASH 2024 | December 4, 2024
Rapamycin can normalize erythroid differentiation in SF3B1-mutated MDS by acting upon the mTOR signaling pathway.
Andrew MorenoASH 2024 | December 6, 2024
US FDA researchers analyzed randomized, controlled, multicenter MDS trials for connections between OS, EFS, CR, and PR.
Andrew MorenoASH 2024 | December 4, 2024
The combination was well-tolerated and the recommended dose determined for the phase II component of an ongoing trial.
Andrew MorenoASH 2024 | December 4, 2024
Cohort patients had at least one prior intervention with luspatercept, lenalidomide, an HMA or ESA, or were ESA-ineligible.
Andrew MorenoMDS | November 14, 2024
The favorable effects from pharmacologic iron restriction may also be enhanced when used with an erythroid maturation agent.
Andrew MorenoMDS | November 12, 2024
Analysts advise that CMML that features AML-associated mutations should undergo management approaches typically used for AML.
Andrew MorenoMDS | November 11, 2024
Expert panel consensus produced a set of genomics-based disease categories from the two systems' morphology-based categories.
Amy DeZern, MD, MHSMDS | December 6, 2024
Clinicians seek alternatives to biopsy for clinically evaluating bone marrow mutations in cytopenic patients.
Andrew MorenoMDS | October 30, 2024
A retrospective study's insights help inform timing decisions regarding allogenic HCT in patients with MDS or CMML.
Patrick DalyMDS | October 30, 2024
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
Julie GouldMDS | October 29, 2024
The COMMANDS trial data underscore luspatercept as the preferred treatment for disease not previously exposed to ESAs.
Advertisement
Advertisement
Advertisement
Latest News

December 11, 2024